^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Zepzelca (lurbinectedin)

    i
    Other names: PM1183, PM01183, PM 1183, PM-01183, LY01017, PM-1183, LY 01017, LY-01017, PM 01183
    Company:
    Boryung Group, EMD Serono, Jazz, Key Oncologics, Luye Group, PharmaMar, Specialised Therap
    Drug class:
    Alkylating agent, Apoptosis stimulant, RNA polymerase inhibitor
    Related drugs:
    4d
    A Prospective, Multicenter, Phase II Clinical Study of Lucansartuzumab Combined with Tislelizumab as Neoadjuvant Therapy for Resectable Stage II–IIIB NSCLC (ChiCTR2600116747)
    P2, N=45, Not yet recruiting, Shanghai Chest Hospital; Shanghai Chest Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation
    |
    Tevimbra (tislelizumab-jsgr) • Zepzelca (lurbinectedin)
    8d
    A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=531, Not yet recruiting, AbbVie
    New P3 trial • Adverse events
    |
    topotecan • Zepzelca (lurbinectedin) • ABBV-706 • Calsed (amrubicin)
    9d
    ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin. (PubMed, Mol Cancer Ther)
    ISL1 serves as both a predictive biomarker and functional dependency, as evidenced by essentiality for cell survival and loss following treatment. Prospective studies using ISL1 as a predictive biomarker for lurbinectedin are planned.
    Journal
    |
    SLFN11 (Schlafen Family Member 11) • RBMS3 (RNA Binding Motif Single Stranded Interacting Protein 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • ATF3 (Activating Transcription Factor 3) • ISL1 (ISL LIM Homeobox 1) • SIX1 (SIX Homeobox 1) • SIX4 (SIX Homeobox 4)
    |
    Zepzelca (lurbinectedin)
    24d
    Personalized drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms. (PubMed, J Clin Endocrinol Metab)
    We provide novel data on the efficacy of putative and established therapies in patient-derived GEP-NEN primary cultures. Our standardized platform for personalized drug screening and risk assessment in GEP-NEN primary cultures enables prediction of individual tumor treatment response in this orphan disease.
    Journal
    |
    CDK4 (Cyclin-dependent kinase 4)
    |
    5-fluorouracil • sunitinib • everolimus • temozolomide • Piqray (alpelisib) • Zejula (niraparib) • Cabometyx (cabozantinib tablet) • Kisqali (ribociclib) • adavosertib (AZD1775) • Truqap (capivasertib) • berzosertib (M6620) • Zepzelca (lurbinectedin) • zoledronic acid
    25d
    ISG-TULIPS: Clinical Study in Patients With DSRCT (clinicaltrials.gov)
    P2, N=20, Recruiting, Italian Sarcoma Group
    New P2 trial
    |
    WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1)
    |
    irinotecan • Zepzelca (lurbinectedin)
    28d
    Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, Mayo Clinic | Trial primary completion date: May 2027 --> Sep 2026
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • Zepzelca (lurbinectedin)
    1m
    Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=46 --> 29
    Enrollment closed • Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • Zepzelca (lurbinectedin)
    1m
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, AbbVie | Trial completion date: May 2029 --> Sep 2031
    Trial completion date • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    1m
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, AbbVie | Trial completion date: Sep 2031 --> May 2029
    Trial completion date • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    2ms
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Phase classification: P2/3 --> P2
    Enrollment open • Phase classification • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    2ms
    Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sichuan University
    New P2 trial
    |
    albumin-bound paclitaxel • etoposide IV • irinotecan • Zepzelca (lurbinectedin)
    3ms
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=180, Not yet recruiting, AbbVie | Trial completion date: May 2029 --> Sep 2031
    Trial completion date • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706